Related Experiment Video
Updated: Sep 23, 2026
A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
Published on: January 27, 2019
Antibiotic therapy in preterm premature rupture of membranes: Are seven days necessary? A preliminary, randomized
David F Lewis1, C David Adair, Alfred G Robichaux
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center, Lexington, USA. dlewi1@lsuhsc.edu
Insights
A 3-day course of ampicillin-sulbactam antibiotic therapy is comparable to a 7-day course for prolonging latency in preterm premature rupture of membranes. More patients are needed to confirm this finding.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Preterm premature rupture of membranes (PPROM) is a significant concern in obstetric care.
- Prolonging latency in PPROM aims to improve neonatal outcomes.
- Broad-spectrum antibiotic therapy is a common strategy to achieve prolonged latency.
Purpose of the Study:
- To compare the efficacy of 3-day versus 7-day ampicillin-sulbactam therapy in prolonging latency in PPROM patients.
- To determine if a shorter antibiotic course is non-inferior to a longer course.
Main Methods:
- A prospective, randomized, intent-to-treat trial was conducted across three study sites.
- Patients with PPROM were randomly assigned to receive either 3 or 7 days of intravenous ampicillin-sulbactam.
- The primary outcome measured was the latency period from membrane rupture to delivery.
Main Results:
- No significant difference in latency period was observed between the 3-day (214 +/- 225 hours) and 7-day (229 +/- 218 hours) groups.
- A significantly higher proportion of patients completed the 3-day therapy course (80.1%) compared to the 7-day course (47.6%).
- No significant differences in other parameters or adverse events were noted between the groups.
Conclusions:
- Three days of ampicillin-sulbactam therapy appears to be as effective as 7 days in prolonging latency for PPROM.
- A shorter antibiotic duration may improve treatment completion rates.
- Further studies with larger sample sizes are warranted to exclude a type II error.
Objective:
The purpose of this study was to determine whether 3 days of broad-spectrum antibiotic therapy, which is intended to prolong latency in patients with preterm premature rupture of membranes, is comparable to 7 days of therapy.
Study Design:
Patients with preterm premature rupture of membranes at three separate study sites were asked to participate in this intent-to-treat, prospective, randomized trial. They were assigned randomly to either 3 or 7 days of ampicillin-sulbactam (3 g intravenously every 6 hours). The primary outcome of interest was the latency period from membrane rupture to delivery.
Results:
Forty-two individuals were enrolled in each group. No difference was noted in the latency interval between the two groups (3 days, 214 +/- 225 hours, vs 7 days, 229 +/- 218 hours). A significantly higher number of patients in the 3-day group completed therapy (80.1% vs 47.6%, P =.003). No other parameters were significantly different between the two groups. No adverse events or trends were noted in either group.
Conclusion:
There appears to be no difference in the latency period between 3 and 7 days of ampicillin-sulbactam antibiotic therapy. More patients are needed to exclude a type II error.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:21Microbiota Modulation by Antibiotics